Agenus Inc. (NASDAQ:AGEN) Receives Average Recommendation of “Hold” from Brokerages

Agenus Inc. (NASDAQ:AGEN) has been assigned a consensus recommendation of “Hold” from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $10.50.

A number of research analysts have weighed in on the company. William Blair downgraded Agenus from an “outperform” rating to a “market perform” rating in a report on Thursday, July 18th. B. Riley lowered their price objective on shares of Agenus from $42.00 to $18.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th. Baird R W lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 19th. Robert W. Baird downgraded shares of Agenus from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $35.00 to $8.00 in a research report on Friday, July 19th. Finally, HC Wainwright downgraded shares of Agenus from a “buy” rating to a “neutral” rating and cut their price objective for the company from $40.00 to $9.00 in a research report on Thursday, July 18th.

Institutional Trading of Agenus

Hedge funds and other institutional investors have recently modified their holdings of the company. Hennion & Walsh Asset Management Inc. lifted its stake in shares of Agenus by 2.5% during the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 558,606 shares of the biotechnology company’s stock valued at $324,000 after buying an additional 13,604 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Agenus by 81.3% in the first quarter. BNP Paribas Financial Markets now owns 188,414 shares of the biotechnology company’s stock valued at $109,000 after acquiring an additional 84,477 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Agenus by 13.7% in the first quarter. Vanguard Group Inc. now owns 34,401,122 shares of the biotechnology company’s stock worth $19,953,000 after acquiring an additional 4,134,232 shares during the period. Acadian Asset Management LLC grew its position in shares of Agenus by 1,959.9% during the first quarter. Acadian Asset Management LLC now owns 757,397 shares of the biotechnology company’s stock worth $439,000 after purchasing an additional 720,629 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in Agenus by 52.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 357,915 shares of the biotechnology company’s stock valued at $208,000 after purchasing an additional 123,058 shares during the period. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Stock Down 1.4 %

Shares of Agenus stock opened at $4.35 on Friday. Agenus has a twelve month low of $4.18 and a twelve month high of $19.69. The company’s 50 day moving average is $5.11 and its 200 day moving average is $9.11. The company has a market cap of $91.35 million, a price-to-earnings ratio of -0.34 and a beta of 1.37.

Agenus (NASDAQ:AGEN) last announced its earnings results on Thursday, August 8th. The biotechnology company reported ($2.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($1.19). The business had revenue of $23.51 million for the quarter, compared to analyst estimates of $64.73 million. During the same period in the previous year, the company posted ($4.00) EPS. Sell-side analysts expect that Agenus will post -10.87 EPS for the current fiscal year.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.